FDA Drug · D-0185-2024

Jardiance (empagliflozin tablets), 25 mg, 30 tablets (3 blister cards with 10 tablets each), Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877. NDC: 0597-0153-37

Class II · Terminated

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Affected lots / codes — check yours against thisBatch D41919

Recalling firm: CARDINAL HEALTHCARE, Dublin, OH
Classification: Class II (temporary or reversible harm possible)
Status: Terminated
Quantity: 1 unit
Distribution: Nationwide USA
Recall initiated: January 26, 2022
Classified: December 26, 2023
Terminated: September 29, 2024
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0185-2024%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →